

1. Record Nr.	UNINA9910746297103321
Titolo	Novel Technologies in Biosystems, Biomedical and Drug Delivery // edited by Shrikaant Kulkarni, A. K. Haghi, and Sonali Manwatkar
Pubbl/distr/stampa	Singapore : , : Springer, , [2023] ©2023
ISBN	981-9952-81-6
Edizione	[First edition.]
Descrizione fisica	1 online resource (0 pages)
Disciplina	610.28
Soggetti	Biomedical engineering Drug delivery systems - Technological innovations
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Intro -- Preface -- Contents -- Contributors -- Abbreviations -- Biosystems: Nature, Relevance and Significance -- Editorial: Bio-Systems: Relevance, Reflection and Impact -- 1 Introduction -- 2 Relevance -- 3 Reflection -- 4 Impact -- 5 System Biology -- 6 Applications -- 7 Regulation of BSs -- 8 Conclusion -- Potential of Biotechnology in Cancer Management -- 1 Introduction -- 2 Current Cancer Epidemiology -- 3 Biotechnology in Cancer Therapy -- 3.1 Monoclonal Antibody -- 3.2 Stem Cell Therapy -- 3.3 Gene Therapy -- 3.4 CAR-T/NK Cell Therapy -- 3.5 Engineered Cytokines -- 3.6 Strategies for Cytokine Engineering -- 3.7 Methods of Cytokine Delivery -- 3.8 Cancer Vaccines -- 3.9 Shared Vaccines -- 3.10 Personalized Vaccines -- 3.11 Ex Vivo Vaccines -- 3.12 In Situ Vaccines -- 3.13 Vaccine Delivery Vehicles -- 4 Biotechnology Approaches Over Traditional Therapy -- 5 Combination Therapy Involving Biotechnology -- 6 Conclusion and Future Perspectives -- References -- Biosimilars: Promising and Rapidly Emerging Biotherapeutics -- 1 Introduction -- 2 Biosimilar Primer -- 3 Biosimilars Approval and Regulatory Requirements -- 4 Biosimilar Manufacturing Process -- 4.1 Choosing a Reference Biological -- 4.2 Process of Manufacturing -- 4.3 Quality Control Consideration -- 5 Specification -- 6 Stability -- 7 Comparison and Quality Analysis -- 8 Nonclinical Studies Data Requirements -- 8.1 Prerequisite Before Conducting Nonclinical Studies -- 8.2 Early-Stage

Research Pharmacodynamic and Toxicology Studies -- 9 Toxicological Studies -- 10 Immunogenicity -- 11 Application Data Requirements for Clinical Trials -- 12 Data Requirements for Market Authorization Applications -- 13 Pharmacovigilance Strategy -- 14 Post-marketing Analysis (Phase IV Study) -- 15 Exceptions -- References -- Biomedicine: Trends, Challenges, Prospects.

Applications of Nanomaterials in Medicine: Current Status and Future Scope -- 1 Introduction -- 2 Nanomedicine-Shifting the Paradigm in Medicine -- 3 Role of Nanomaterials in Treatment -- 3.1 Application of Nanomaterials as Antimicrobial and Antiviral Agents -- 4 Cancers -- 4.1 Breast Cancer -- 4.2 Lung Cancer -- 4.3 Oral Cancer -- 4.4 Pancreatic Cancer -- 4.5 Leukemia -- 5 Respiratory Disorders -- 5.1 COPD -- 5.2 Asthma -- 5.3 Pneumonia -- 5.4 Cystic Fibrosis -- 6 Ocular Diseases -- 6.1 Glaucoma -- 6.2 Cataract -- 6.3 Pterygium -- 6.4 Conjunctivitis -- 7 Disease of Immune System -- 7.1 Arthritis -- 7.2 Aids -- 7.3 Autoimmune Disease -- 7.4 Disease of Thyroid Gland -- 8 Cardiovascular Diseases -- 8.1 Ischemic Heart Diseases -- 8.2 Arteriosclerosis -- 8.3 Atherosclerosis -- 9 Metabolic Disorders -- 9.1 Diabetes -- 9.2 Inflammatory Bowel Disease -- 9.3 Hyperlipidemia -- 10 Tissue Engineering -- 10.1 Periodontitis -- 10.2 Bone Tissue -- 10.3 Regeneration of Nerves -- 11 Role of Nanomaterials in Diagnosis -- 11.1 Detection of Pathogens -- 11.2 Role in Imaging -- 12 Manipulation of Cells and DNA Tagging -- 13 Dual Nanotools for Diagnostics and Therapeutics -- 14 Nanomaterials-Drug Delivery and Bioavailability -- 15 Environmental Considerations -- 16 Future Scope of Nanomedicine -- References -- Biomedical Applications of Nanofluids in Drug Delivery -- 1 Introduction -- 2 Nanofluid Preparation -- 2.1 One Step Method -- 2.2 Two-Step Method -- 3 Characterization of Nanofluids -- 4 Advantages of Nanofluid -- 5 Application in the Biomedical Field (Fig. 3) -- 5.1 Cancer Treatment -- 5.2 Antimicrobial Activity -- 5.3 Drug Delivery -- 5.4 Wound Care -- 5.5 Cryopreservation -- 5.6 Cryosurgery -- 5.7 Bioimaging -- 5.8 Micro-Pumping Devices -- 6 Challenges -- 7 Future Scope -- 8 Conclusions -- References -- Metagenomics for Drug Discovery -- 1 Introduction to Drugs.

1.1 What Are Drugs? -- 1.2 Historical Background of Drugs -- 1.3 General Pipeline for Drug Discovery and Development -- 1.4 Need for Newer Drug Discoveries -- 2 Current Approaches for Microbial-Derived Drug Discovery -- 2.1 Unique Habitats and Novel Metabolites -- 2.2 Conventional and Emerging Cultivation Techniques -- 3 Role of Metagenomics in Drug Discovery -- 3.1 Metagenomics Approach for Bioprospecting -- 3.2 Techniques Involved in Metagenomics -- 3.3 Metagenomics for Bioprospecting Drug Synthesizing Potential of Microbes -- 4 Conclusion -- References -- Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy -- 1 Introduction -- 2 EGFR-TK Inhibitors as a Target for Tumors -- 2.1 Structural and Physiological Functions of EGFR -- 2.2 Extracellular Domains -- 2.3 Tyrosine-Kinase Domains -- 2.4 Activation and Role of EGFR -- 2.5 Different Strategies for Inhibition of EGFR-TK -- 3 Role of Heterocyclic Compounds as EGFR Inhibitor -- 4 Multi-targets TK Inhibitors -- 5 Quinoline -- 5.1 Natural Sources of Quinoline -- 5.2 FDA Approved Quinoline Drugs -- 5.3 Quinoline as EGFR Inhibitor -- 6 Pyrazole as EGFR Inhibitor -- 7 Pyrimidine as EGFR Inhibitors -- 7.1 Pyrimidine Derivatives -- 7.2 Amino-Pyrimidine Derivatives -- 7.3 D2,4-Diamino Substituted Pyrimidine Derivatives -- 7.4 D4,6-Diamino Substituted Pyrimidine Derivatives -- 8 Pyrrolo-Pyrimidine Derivatives -- 8.1 Pyrazolo-Pyrimidine Containing Compounds -- 8.2 Pyrido-Pyrimidine Based Compounds -- 8.3 Pyrimido-Pyrimidine Derivatives -- 8.4 Furo-

Pyrimidine Based Compounds -- 8.5 Thieno-Pyrimidine Derivatives -- 8.6 Thiopyrano-Pyrimidine Derivatives -- 9 Miscellaneous Derivatives -- 9.1 Coumarin Based EGFR-TK Inhibitors -- 10 Conclusion -- References -- Drug Delivery Systems: Current Trends, and Advances -- Potential of Nanocrystalline Drug Delivery Systems -- 1 Introduction. 1.1 History -- 1.2 Properties of Nanocrystals -- 1.3 Benefits of Nanocrystals -- 1.4 Drawback of Nanocrystals -- 2 Methods/Technology (Rath et al. 2008 -- Ohara et al. 2008 -- Kwon et al. 2006 -- Felgner et al. 2004 -- Ren et al. 2011 -- Anuradha et al. 2001 -- Zeng and Li 1999 -- Sahoo et al. 2007) -- 2.1 Bottom-Up Technique -- 2.2 Top Down: (Milling and Homogenization) (Ohara et al. 2008 -- Kwon et al. 2006 -- Felgner et al. 2004 -- Ren et al. 2011 -- Anuradha et al. 2001 -- Zeng and Li 1999 -- Sahoo et al. 2007) -- 2.3 Spray Drying -- 3 Supplementary Technologies (Sahoo et al. 2007 -- Fang et al. 2008 -- Buscaglia et al. 2005 -- Hennings et al. 2001 -- Roy and Mohanta 2009 -- Abdelwahed et al. 2006 -- Ali et al. 2011) -- 3.1 'Rapid Expansion From a Liquefied-Gas Solution (RESS)' -- 3.2 'Nanopure® XP Technology' -- 3.3 'Spray Freezing into Fluid (Liquid) (SFL)' -- 3.4 "Solvent Evaporation" -- 3.5 Sonocrystallization -- 3.6 'Melt Emulsification Technique' -- 4 Characterization of Nano Crystals (Cerdeira et al. 2010 -- Chan and Kwok 2011 -- Deschamps et al. 2009 -- Dong et al. 2010 -- Eerdenbrugh et al. 2008 -- Faure et al. 2001) -- 5 Comparison of the Benefits of Other Drug Delivery Systems and Nanocrystalline Drugs Delivery Systems (Ganta et al. 2009 -- Gao et al. 2008a, b) -- 6 Examples (Marketed Formulation of Nanocrystals) (Ghosh et al. 2012 -- Hanafy et al. 2007) -- 7 Conclusions -- References -- Novel Techniques in Pulmonary Drug Delivery Systems -- 1 Introduction to Pulmonary Drug Delivery Systems (PDDS) -- 2 Respiratory Tract as a Target for PDDS -- 2.1 Respiration Physiology -- 2.2 Classification of Anti Asthmatic and COPD Drugs -- 3 Patient Related Factors -- 3.1 Respiratory Tract's Anatomy and Physiology -- 3.2 Inhalation Flow Rate -- 3.3 Inhalation Mode -- 4 Physical Properties -- 4.1 Properties of Pure Drug. 4.2 Properties of Excipient Carrier System -- 4.3 Formulation Related Factors -- 5 Lung Diseases and Its Treatment by Various Dosage Forms Such as DPI's, MDI's and Nebulizers -- 5.1 Asthma -- 5.2 Types of Asthma -- 5.3 Pathophysiology of Asthma -- 5.4 Diagnosis -- 5.5 Chronic Obstructive Pulmonary Disease -- 5.6 Types of COPD -- 5.7 Treatment of COPD -- 6 Treatment of Asthma and Other Lung Diseases with DPI's, MDI's and Nebulizers -- 7 Analytical Testing of DPI's, MDI's and Nebulizers -- 8 Conclusion -- References -- Proteomics: Scope and Potential -- Proteomics in Oncology: Retrospect and Prospects -- 1 Introduction -- 1.1 Genomic Approaches -- 1.2 Transcriptomic Approaches -- 1.3 Various Areas of Proteomics -- 1.4 Protein Discovery -- 1.5 The Comparison and Profiling Method for Proteomes -- 2 Proteomics Type -- 3 Proteomics of Expression -- 4 Structural Proteomics -- 5 Multiplexed Proteomic Tools: Proteomic Pattern Diagnostic -- 6 Methods for Quantitating and Identifying Proteins -- 7 Isobaric Labelling for Multiplexed Proteomics -- 8 Principles for Quantitative Multiplexed Proteomics -- 9 Innovative Proteomics Technologies -- 9.1 Targeted Multiplexed Proteomics -- 9.2 Multiplexed Proteomics Implementation with Data Independent Acquisition -- 9.3 Proteomics Pattern Diagnostics -- 10 Methods of Proteomics -- 10.1 Two-Dimensional Gel Electrophoresis (2DGE) and Mass Spectrometry -- 10.2 Matrix-Assisted Laser Desorption/Ionization (MALDI) -- 10.3 Electrospray Ionization (ESI) -- 10.4 Aptamer-Based Assays -- 11 Bioinformatics in Proteomics -- 12 Application of Proteomics in Cancer -- 12.1 Cancer Growth -- 12.2

Metastasis -- 13 Drug Resistance -- 14 Clinical Proteomic Tools
for Patient Tailored Therapeutics -- References -- Proteomics Novel
Prospects in Target Therapy for Infectious Diseases -- 1 Introduction
-- 2 Drawbacks of Current Strategies.
3 Proteomics.
